HRP20191826T4 - Derivati n-piridinil acetamida kao inhibitori wnt signalnog puta - Google Patents
Derivati n-piridinil acetamida kao inhibitori wnt signalnog puta Download PDFInfo
- Publication number
- HRP20191826T4 HRP20191826T4 HRP20191826TT HRP20191826T HRP20191826T4 HR P20191826 T4 HRP20191826 T4 HR P20191826T4 HR P20191826T T HRP20191826T T HR P20191826TT HR P20191826 T HRP20191826 T HR P20191826T HR P20191826 T4 HRP20191826 T4 HR P20191826T4
- Authority
- HR
- Croatia
- Prior art keywords
- cancer
- compound according
- image
- substituted
- haloalkyl
- Prior art date
Links
- MIQSEHQDHNIQNF-UHFFFAOYSA-N N-(2H-pyridin-1-yl)acetamide Chemical class CC(=O)NN1CC=CC=C1 MIQSEHQDHNIQNF-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000019491 signal transduction Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 18
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 8
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 7
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 7
- 201000000582 Retinoblastoma Diseases 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 4
- 206010058202 Cystoid macular oedema Diseases 0.000 claims 4
- 101000743846 Diplobatis ommata Ras-related protein Rab-10 Proteins 0.000 claims 4
- 208000001344 Macular Edema Diseases 0.000 claims 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 4
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 4
- 201000010206 cystoid macular edema Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010060862 Prostate cancer Diseases 0.000 claims 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims 2
- HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 2
- 208000003174 Brain Neoplasms Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- 206010023421 Kidney fibrosis Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 101100408855 Mus musculus Porcn gene Proteins 0.000 claims 2
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims 2
- 206010050207 Skin fibrosis Diseases 0.000 claims 2
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 2
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 208000008383 Wilms tumor Diseases 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 239000011737 fluorine Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 201000010536 head and neck cancer Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 2
- 201000005787 hematologic cancer Diseases 0.000 claims 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 201000008968 osteosarcoma Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 201000001474 proteinuria Diseases 0.000 claims 2
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims 2
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- CXWGKAYMVASWDQ-UHFFFAOYSA-N 1,2-dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 claims 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 claims 1
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 claims 1
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 claims 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- LOZWAPSEEHRYPG-UHFFFAOYSA-N dithiane Natural products C1CSCCS1 LOZWAPSEEHRYPG-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000010749 gastric carcinoma Diseases 0.000 claims 1
- 125000005347 halocycloalkyl group Chemical group 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- IVMHDOBGNQOUHO-UHFFFAOYSA-N oxathiane Chemical compound C1CCSOC1 IVMHDOBGNQOUHO-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Chemical group 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000000498 stomach carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Transplantation (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
Claims (17)
1. Spoj formule (III):
[image]
pri čemu
X1 i X2 su odabrani između CR6 i N, pri čemu je jedan od X1 i X2 CR6, a drugi je N; het2 je 5 ili 6 člani heterociklični prsten koji može biti nesupstituiran ili supstituiran, a kada je supstituiran prsten je supstituiran s 1, 2 ili 3 skupine koje su neovisno odabrane pri svakom pojavljivanju od: halo, C1-4 alkil, C1-4 haloalkil, -ORA1, -NRA1RB1, -CN, -NO2, -NRA1C(O)RB1, -C(O)NRA1RB1, -NRA1SO2RB1, -SO2NRA1RB1, -SO2RA1, -C(O)RA1, -C(O)ORA1 i C3-6 cikloalkil;
het3 je 5 ili 6 člani heterociklični prsten ili fenilni prsten koji može biti nesupstituiran ili supstituiran, a kada je supstituiran prsten je supstituiran s 1, 2 ili 3 skupine koje su neovisno odabrane i pri svakom pojavljivanju od: halo, C1-4 alkil, C1-4 haloalkil, -ORA1, -NRA1RB1, -CN, -NO2, -NRA1C(O)RB1,-C(O)NRA1RB1, -NRA1SO2RB1, -SO2NRA1RB1, -SO2RA1, -C(O)RA1, -C(O)ORA1 i C3-6 cikloalkil;
R1 i R2 su nezavisno odabrani, a pri svakom pojavljivanju od: H, halo, C1-4 alkil, C1-4 haloalkil, - ORA3, -NRA3RB3 i C3-6 cikloalkil;
R3 je odabran od: H, C1-4 alkil, C1-4 haloalkil, i C3-6 cikloalkil;
R4 je neovisno odabran pri svakom pojavljivanju od: halo, C1-4 alkil, C1-4 haloalkil, -CN, -ORA4,-NRA4RB4, -SO2RA4, C3-6 cikloalkil i C3-6 halocikloalkil;
R5 i R6 su, pri svakom pojavljivanju, neovisno odabrani između: H, halo, C1-4 alkil, C1-4 haloalkil, -ORA2, -NRA2RB2, -CN, -SO2RA2, i C3-6 cikloalkil;
m je odabran od 1, 2 ili 3;
n je odabran od 0, 1 ili 2; i
RA1, RB1, RA2, RB2, RA3, RB3, RA4 i RB4 se pri svakom pojavljivanju neovisno bira i od: H, C1-4 alkil, C1-4 haloalkil.
2. Spoj prema zahtjevu 1, naznačen time, da:
het2 je 5 ili 6 člani heterociklični prsten koji može biti nesupstituiran ili supstituiran, a kada je supstituiran prsten je supstituiran s 1, 2 ili 3 skupine koje su odabrane od: halo, C1-4 alkil, C1-4 haloalkil, - ORA1, -NO2, -NRA1C(O)RB1, -NRA1SO2RB1, -SO2NRA1RB1, -SO2RA1, -C(O)RA1, -C(O)ORA1 i C3-6 cikloalkil;
pod uvjetom da ako het2 nije piridil; ili
het2 predstavlja prsten odabran od nesupstituiranog ili supstituiranog: pirazola, imidazola, piridina, pirazina, pirimidina, piridazina, pirana, tetrahidropirana, dihidropirana, piperidina, piperazina, morfolina, tiomorfolina, oksazina, dioksina, dioksana, tiazina, oksatiana i ditiana.
3. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time, da het3 predstavlja aromatski, zasićen ili nezasićen 6-člani heterociklički prsten koji je nesupstituiran ili je supstituiran i sadrži najmanje jedan atom dušika, po izboru gdje je het3 prsten koji se bira između nesupstituiranog ili supstituiranog: pirimidina, pirazina, piridazina, piperazina, dioksina, dioksana, morfolina i tiomorfolina.
4. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time, da se R1 i R2 mogu neovisno birati pri svakom pojavljivanju od: H, klora, fluora, metila, etila, tri fluormetila, tri fluoretila, -OCF3, -OH, - OMe, -OEt, -NH2, -NHMe, i -NMe2.
5. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time, da R3 predstavlja H ili metil.
6. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time, da R4 je nezavisno izabran pri svakom pojavljivanju od: H, klora, fluora, metila, etila, trifluorometila, trifluoroetila, -OCF3, -OH, -OMe, - OEt, -NH2, -NHMe, i -NMe2.
7. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time, da m je 1.
8. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time da n je 0.
9. Spoj prema zahtjevu 1, naznačen time, da je spoj je izabran između:
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
[image]
10. Spoj prema bilo kojem prethodnom zahtjevu, naznačen time da se upotrebljava kao lijek.
11. Spoj prema bilo kojem od zahtjeva 1 do 9, naznačen time, da je spoj za uporabu u modulaciji Wnt signaliziranja.
12. Spoj prema bilo kojem od zahtjeva 1 do 9, naznačen time, da se upotrebljava u liječenju stanja koje se može modulirati inhibicijom Porcn, opcijski gdje se stanje koje se može liječiti inhibicijom Porcn bira između: karcinoma, sarkoma, melanoma, raka kože, hematoloških tumora, limfoma, karcinoma i leukemije, nadalje opcijski gdje se stanje bira između: karcinoma pločastih stanica jednjaka, karcinoma želuca, glioblastoma, astrocitoma; retinoblastoma, osteosarkoma, hondosarkoma, Ewingova sarkoma, rabdomisarkoma, Wilmova tumora, bazalnocelularnog karcinoma, ne-staničnog karcinoma pluća, tumora mozga, hormonskog refraktornog karcinoms prostate, raks prostate, metastatskog raka dojke, karcinoma dojke, metastatskog karcinoma gušterače, raka gušterače, kolorektalnog karcinoma, raka grlića maternice, pločastog staničnog karcinoma glave i vrata i raka glave i vrata ili pri čemu je stanje odabrano između: kožne fibroze, idiopatske plućne fibroza, bubrežne intersticijska fibroze, fibroze jetre, proteinurije, odbacivanja bubrežnog grafta, osteoartritisa, Parkinsonove bolesti, cistoidnog makularnog edema, cistoidnog makularnog edemapovezanog s uveitisom, retinopatije, dijabetičke retinopatije i retinopatije prijevremenog rođenja.
13. Spoj prema bilo kojem od zahtjeva 1 do 9, naznačen time, da se upotrebljava u liječenju stanja odabranog između:
karcinoma, sarkoma, melanoma, raka kože, hematoloških tumora, limfoma, karcinoma i leukemije.
14. Spoj prema zahtjevu 13, naznačen time da je stanje odabrano: karcinoma pločastih stanica jednjaka, raka želuca, glioblastoma, astrocitoma; retinoblastoma, osteosarkoma, hondosarkoma, Ewingova sarkoma, rabdomisarkoma, Wilmova tumora, bazalnocelularnog karcinoma, ne-sitnostaničnog raka pluća, tumora mozga, refraktornog hormonalnog raka prostate, raka prostate, metastatskog karcinoma dojke, raka dojke, metastatskog karcinoma gušterače, raka gušterače, kolorektalnog karcinoma, raka grlića maternice, karcinoma pločastih stanica glave i vrata i raka glave i vrata.
15. Spoj prema zahtjevu 13, naznačen time da je stanje izabrano između: fibroze kože, idiopatske plućne fibroze, intersticijske fibroze bubrega, fibroze jetre, proteinurije, odbacivanja bubrežnih presadaka, osteoartritisa, Parkinsonove bolesti, cistoidnog makularnog edema, cistoidnog makularnog edema povezanog s uveitisom, retinopatije, dijabetičke retinopatije i retinopatije prijevremenog rođenja.
16. Farmaceutska formulacija koja sadrži spoj prema bilo kojem od zahtjeva 1 do 9 i farmaceutski prihvatljivo pomoćno sredstvo.
17. Farmaceutski pripravak prema zahtjevu 16, naznačen time što je farmaceutski pripravak kombinirani proizvod koji obuhvaća dodatno farmaceutski aktivno sredstvo.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1417829.7A GB201417829D0 (en) | 2014-10-08 | 2014-10-08 | Compounds |
| GBGB1511387.1A GB201511387D0 (en) | 2015-06-29 | 2015-06-29 | Compounds |
| EP15782041.6A EP3204378B3 (en) | 2014-10-08 | 2015-10-08 | N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway |
| PCT/GB2015/052939 WO2016055786A1 (en) | 2014-10-08 | 2015-10-08 | N-pyridinyl acetamide derivatives as inhibitors of the wnt signalling pathway |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20191826T1 HRP20191826T1 (hr) | 2020-01-10 |
| HRP20191826T4 true HRP20191826T4 (hr) | 2022-08-05 |
Family
ID=54337304
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20191826TT HRP20191826T4 (hr) | 2014-10-08 | 2015-10-08 | Derivati n-piridinil acetamida kao inhibitori wnt signalnog puta |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US10047079B2 (hr) |
| EP (1) | EP3204378B3 (hr) |
| JP (2) | JP6722178B2 (hr) |
| KR (1) | KR102525131B1 (hr) |
| CN (1) | CN107108565B (hr) |
| AU (1) | AU2015329784C1 (hr) |
| CA (1) | CA2960446C (hr) |
| CY (1) | CY1122243T1 (hr) |
| DK (1) | DK3204378T6 (hr) |
| EA (1) | EA034822B9 (hr) |
| ES (1) | ES2754349T7 (hr) |
| HR (1) | HRP20191826T4 (hr) |
| HU (1) | HUE046914T2 (hr) |
| IL (1) | IL251131B (hr) |
| LT (1) | LT3204378T (hr) |
| MX (1) | MX373651B (hr) |
| PH (1) | PH12017500611A1 (hr) |
| PL (1) | PL3204378T6 (hr) |
| PT (1) | PT3204378T (hr) |
| SG (1) | SG11201701837UA (hr) |
| SI (1) | SI3204378T1 (hr) |
| SM (1) | SMT201900615T1 (hr) |
| WO (1) | WO2016055786A1 (hr) |
| ZA (1) | ZA201701842B (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10047079B2 (en) | 2014-10-08 | 2018-08-14 | Redx Pharma Plc | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway |
| WO2016055790A1 (en) | 2014-10-08 | 2016-04-14 | Redx Pharma Plc | N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| US10793544B2 (en) | 2016-09-01 | 2020-10-06 | The Board Of Regents Of The University Of Texas System | Disubstituted and trisubstituted 1,2,3-triazoles as Wnt inhibitors |
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| JP2019064975A (ja) * | 2017-10-03 | 2019-04-25 | 国立大学法人 熊本大学 | 抗がん剤 |
| WO2019106146A1 (en) | 2017-11-30 | 2019-06-06 | Step Pharma S.A.S. | Compounds |
| CN119823032A (zh) | 2018-02-01 | 2025-04-15 | 悉尼大学 | 抗癌化合物 |
| HUE057970T2 (hu) | 2018-03-08 | 2022-06-28 | Incyte Corp | Aminopirazindiol-vegyületek mint PI3K-Y inhibitorok |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| US10961534B2 (en) | 2018-07-13 | 2021-03-30 | University of Pittsburgh—of the Commonwealth System of Higher Education | Methods of treating porphyria |
| CA3165424A1 (en) | 2019-12-20 | 2021-06-24 | Tenaya Therapeutics, Inc. | Fluoroalkyl-oxadiazoles and uses thereof |
| US20230404985A1 (en) * | 2020-11-02 | 2023-12-21 | Icahn School Of Medicine At Mount Sinai | Methods of treating tumors and cancers having dysregulated wnt signaling pathways |
| GB202100526D0 (en) | 2021-01-15 | 2021-03-03 | Redx Pharma Plc | Pharmaceutical formulation |
| KR20240016950A (ko) | 2021-05-04 | 2024-02-06 | 테나야 테라퓨틱스, 인코포레이티드 | 대사 질환 및 hfpef의 치료에 사용하기 위한 2-플루오로알킬-1,3,4-옥사디아졸-5-일-티아졸, hdac6 억제제 |
| CN118255746A (zh) * | 2022-12-27 | 2024-06-28 | 南京圣和药业股份有限公司 | 选择性cdk12/13抑制剂及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA003056B1 (ru) | 1996-12-23 | 2002-12-26 | Дюпон Фармасьютикалз Компани | АЗОТСОДЕРЖАЩИЕ ГЕТЕРОАРОМАТИЧЕСКИЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И СПОСОБ ЛЕЧЕНИЯ |
| ATE236890T1 (de) | 1996-12-23 | 2003-04-15 | Bristol Myers Squibb Pharma Co | Sauerstoff oder schwefel enthaltende 5-gliedrige heteroaromatishe derivative als factor xa hemmer |
| GB0226583D0 (en) | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| SE0203654D0 (sv) | 2002-12-09 | 2002-12-09 | Astrazeneca Ab | New compounds |
| EP1594847A2 (en) * | 2003-02-12 | 2005-11-16 | Transtech Pharma, Inc. | Substituted azole derivatives as therapeutic agents |
| WO2006040526A1 (en) | 2004-10-12 | 2006-04-20 | Astrazeneca Ab | Quinazoline derivatives for use against cancer |
| WO2008137408A1 (en) * | 2007-04-30 | 2008-11-13 | Genentech, Inc. | Pyrazole inhibitors of wnt signaling |
| CA2707492A1 (en) | 2007-12-13 | 2009-06-18 | Amgen Inc. | Gamma secretase modulators |
| UA103918C2 (en) * | 2009-03-02 | 2013-12-10 | Айерем Элелси | N-(hetero)aryl, 2-(hetero)aryl-substituted acetamides for use as wnt signaling modulators |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| UY33469A (es) * | 2010-06-29 | 2012-01-31 | Irm Llc Y Novartis Ag | Composiciones y metodos para modular la via de señalizacion de wnt |
| BR112013019280A2 (pt) * | 2011-01-28 | 2017-03-21 | Univ Leland Stanford Junior | composições wnt e métodos para sua utilização |
| US20150125857A1 (en) * | 2012-02-28 | 2015-05-07 | Novartis Ag | CANCER PATIENT SELECTION FOR ADMINISTRATION OF Wnt SIGNALING INHIBITORS USING RNF43 MUTATION STATUS |
| GB2513403A (en) | 2013-04-26 | 2014-10-29 | Agency Science Tech & Res | WNT pathway modulators |
| US10047079B2 (en) | 2014-10-08 | 2018-08-14 | Redx Pharma Plc | N-pyridinyl acetamide derivatives as inhibitors of the Wnt signaling pathway |
| WO2016055790A1 (en) | 2014-10-08 | 2016-04-14 | Redx Pharma Plc | N-pyridinyl acetamide derivatives as wnt signalling pathway inhibitors |
-
2015
- 2015-10-08 US US15/514,046 patent/US10047079B2/en active Active
- 2015-10-08 CA CA2960446A patent/CA2960446C/en active Active
- 2015-10-08 ES ES15782041T patent/ES2754349T7/es active Active
- 2015-10-08 EA EA201790637A patent/EA034822B9/ru unknown
- 2015-10-08 HR HRP20191826TT patent/HRP20191826T4/hr unknown
- 2015-10-08 PL PL15782041.6T patent/PL3204378T6/pl unknown
- 2015-10-08 LT LT15782041T patent/LT3204378T/lt unknown
- 2015-10-08 SG SG11201701837UA patent/SG11201701837UA/en unknown
- 2015-10-08 HU HUE15782041A patent/HUE046914T2/hu unknown
- 2015-10-08 SI SI201530941T patent/SI3204378T1/sl unknown
- 2015-10-08 DK DK15782041.6T patent/DK3204378T6/da active
- 2015-10-08 SM SM20190615T patent/SMT201900615T1/it unknown
- 2015-10-08 JP JP2017518951A patent/JP6722178B2/ja active Active
- 2015-10-08 EP EP15782041.6A patent/EP3204378B3/en active Active
- 2015-10-08 AU AU2015329784A patent/AU2015329784C1/en active Active
- 2015-10-08 PT PT157820416T patent/PT3204378T/pt unknown
- 2015-10-08 CN CN201580054724.7A patent/CN107108565B/zh active Active
- 2015-10-08 MX MX2017004637A patent/MX373651B/es active IP Right Grant
- 2015-10-08 KR KR1020177011823A patent/KR102525131B1/ko active Active
- 2015-10-08 WO PCT/GB2015/052939 patent/WO2016055786A1/en active Application Filing
-
2017
- 2017-03-13 IL IL251131A patent/IL251131B/en active IP Right Grant
- 2017-03-15 ZA ZA2017/01842A patent/ZA201701842B/en unknown
- 2017-04-03 PH PH12017500611A patent/PH12017500611A1/en unknown
-
2018
- 2018-07-17 US US16/037,879 patent/US10793560B2/en active Active
-
2019
- 2019-10-10 CY CY20191101069T patent/CY1122243T1/el unknown
-
2020
- 2020-02-17 JP JP2020024726A patent/JP2020090542A/ja not_active Withdrawn
- 2020-09-01 US US17/009,322 patent/US11643408B2/en active Active
-
2023
- 2023-04-03 US US18/130,059 patent/US12202826B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191826T4 (hr) | Derivati n-piridinil acetamida kao inhibitori wnt signalnog puta | |
| PH12016501440A1 (en) | Novel heterocyclic compounds | |
| PH12020551315A1 (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
| PH12017502246A1 (en) | New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them | |
| HRP20230400T1 (hr) | Benzilamino supstituirani piridopirimidinoni i derivati kao inhibitori sos1 | |
| HRP20220864T1 (hr) | Derivati n-piridinil acetamida kao inhibitori signalnog puta wnt | |
| MX2017008520A (es) | Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih). | |
| MY192521A (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
| JOP20190090B1 (ar) | مشتقات 9،8،7،6-رابع هيدرو-3h-بيرازولو [4،3-f]أيزوكينولين مفيدة في علاج السرطان | |
| PH12015502615B1 (en) | Chemical compounds | |
| PH12018500987A1 (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
| NZ629432A (en) | Heterocyclyl compounds as mek inhibitors | |
| MX2017008518A (es) | Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih). | |
| HRP20190805T1 (hr) | Spojevi triazolopirimidina i njihova uporaba | |
| PH12012500752A1 (en) | Benzimidazole-imidazole derivatives | |
| MY192641A (en) | Novel pyrimidine and pyridine compounds and their usage | |
| GEP201706778B (en) | Pyridinyl and fused pyridinyl triazolone derivatives | |
| ME03723B (me) | 2-amin0-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridini kао васе1 inhibiтori | |
| TW201613864A (en) | Novel compounds | |
| EA201792374A1 (ru) | Азабензимидазолы и их применение в качестве модуляторов рецептора ampa | |
| SG10201810361TA (en) | 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus rna replication | |
| HRP20192041T1 (hr) | [derivati 7-(morfolinil)-2-(n-piperazinil) metil tieno [2, 3-c]piridina kao lijekovi protiv raka] | |
| MY193041A (en) | Novel fused imidazobenzothiazole compounds | |
| MX2014003455A (es) | Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide. |